Translational research on vaccines: Influenza as an example

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 6, 2007, Pages 745-749

  Belshe, R B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; DNA VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PEPTIDE; POLYNUCLEOTIDE; RECOMBINANT PROTEIN; VIRUS VECTOR;

ADJUVANT THERAPY; BIOLOGY; EXPRESSION VECTOR; GOVERNMENT; HUMAN; IMMUNOGENICITY; INFLUENZA; NONHUMAN; PRIORITY JOURNAL; RESEARCH; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL CULTURE TECHNIQUES; CHILD, PRESCHOOL; EGGS; HUMANS; INFLUENZA VACCINES; VACCINES, ATTENUATED; VACCINES, CONJUGATE; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 36148971243     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100419     Document Type: Review

References (18)

1. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 55, 1-42 (2006).
2. World Health Organization. Influenza vaccine manufacturers 〈http://www.who.int/csr/disease/influenza/manulist/en/〉. Accessed 12 June 2007.
3. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases 10th edn. (Public Health Foundation, Washington, DC, 2007).
4. Belshe, R.B. et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685-696 (2007).
5. Patriarca, P.A. Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations. World Health Organization 〈http://www.who.int/ vaccine_research/diseases/influenza/WHO_Flu_Cell_Substrate_Version3.pdf〉. Updated 10 April 2007, accessed 12 June 2007.
6. Reisinger, K.S., Block, S.L., Bugarini, R. & Holmes, S. Safety, tolerability and immunogenicity of a Madin-Darby canine kidney cell-based influenza vaccine compared to Fluvirin®: a phase II study. Abstract presented at Options for the Control of Influenza VI, Toronto, ON, Canada, no. P717, 17-23 June 2007.
7. Hardy, C.T., Young, S.A., Webster, R.G., Naeve, C.W. & Owens, R.J. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology 211, 302-306 (1995).
8. Harmon, M.W., Rota, P.A., Walls, H.H. & Kendal, A.P. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J. Clin. Microbiol. 26, 333-337 (1988).
9. Ito, T. et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J. Virol. 71, 3357-3362 (1997).
10. Katz, J.M., Naeve, C.W. & Webster, R.G. Host cell-mediated variation in H3N2 influenza viruses. Virology 156, 386-395 (1987).
11. Katz, J.M. & Webster, R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160, 191-198 (1989).
12. Robertson, J.S. Clinical influenza virus and the embryonated hen's egg. Rev. Med. Virol. 3, 97-106 (1993).
13. Robertson, J.S. et al. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143, 166-174 (1985).
14. Subbarao, K. & Katz, J.M. Influenza vaccines generated by reverse genetics. Curr. Top. Microbiol. Immunol. 283, 313-342 (2004).
15. Treanor, J.J. et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine. J. Am. Med. Assoc. 297, 1577-1582 (2007).
16. Belshe, R.B., Maassab, H.F. & Mendelman, P.M. Influenza vaccine - live. In Vaccines 4th edn. (eds. Plotkin, S.A., Orenstein, W.A. & Offit, P.A.) 371-388 (Elsevier, Philadelphia, PA, 2004).
17. Vesikari, T. et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr. Infect. Dis. J. 25, 590-595 (2006).
18. Izurieta, H.S. et al. Adverse events reported following live-cold-adapted, intranasal influenza vaccine. J. Am. Med. Assoc. 294, 2720-2725 (2005).